A phase 3 clinical trial has found that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, produces a significantly greater reduction in a key marker of kidney damage compared to placebo in adults with Type 1 diabetes and chronic kidney disease (CKD). The results were published on March 5, 2026 in the New England Journal of Medicine.

For anyone who has spent time hiking wooded trails, camping, or simply walking through tall grass, the fear of a tiny tick causing outsized harm is very real. Lyme disease has quietly become one of the most common infectious diseases in the Northern Hemisphere, and yet, for years, doctors have had no vaccine to offer patients. That may be about to change.

On March 23, 2026, Pfizer and French biotech Valneva announced results from their landmark Phase 3 VALOR trial and the numbers are genuinely encouraging.

India has moved a decisive step closer to having its first tetravalent dengue vaccine on the market after a Subject Expert Committee (SEC) under the Drugs Controller General of India (DCGI) recommended approving Takeda Biopharmaceuticals' Dengue Tetravalent Vaccine (TDV) for import and use in individuals aged 4 to 60 years.